Revvity FY2025 EPS Estimate Increased by Zacks Research

Revvity Inc. (NYSE:RVTY) – Equities researchers at Zacks Research increased their FY2025 EPS estimates for Revvity in a research note issued on Monday, November 17th. Zacks Research analyst Team now anticipates that the company will earn $4.91 per share for the year, up from their previous forecast of $4.86. The consensus estimate for Revvity’s current full-year earnings is $4.94 per share. Zacks Research also issued estimates for Revvity’s Q4 2025 earnings at $1.54 EPS, Q1 2026 earnings at $1.13 EPS, Q2 2026 earnings at $1.30 EPS, Q3 2026 earnings at $1.29 EPS, Q4 2026 earnings at $1.58 EPS, FY2026 earnings at $5.30 EPS, Q1 2027 earnings at $1.29 EPS, Q2 2027 earnings at $1.51 EPS, Q3 2027 earnings at $1.49 EPS and FY2027 earnings at $6.00 EPS.

A number of other analysts have also commented on RVTY. Stifel Nicolaus dropped their price target on Revvity from $120.00 to $110.00 and set a “hold” rating on the stock in a report on Tuesday, July 29th. Barclays lifted their target price on Revvity from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 28th. Robert W. Baird boosted their price target on shares of Revvity from $122.00 to $123.00 and gave the stock an “outperform” rating in a report on Tuesday, October 28th. Evercore ISI restated an “outperform” rating and set a $108.00 price objective on shares of Revvity in a report on Monday, October 27th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Revvity in a research report on Thursday, November 13th. Eight investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $114.75.

Revvity Price Performance

Shares of NYSE RVTY opened at $93.16 on Tuesday. The company has a market capitalization of $10.56 billion, a PE ratio of 46.81, a PEG ratio of 3.15 and a beta of 1.01. The company has a quick ratio of 2.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.36. The stock’s 50 day moving average price is $90.76 and its 200-day moving average price is $92.22. Revvity has a twelve month low of $81.36 and a twelve month high of $128.29.

Revvity (NYSE:RVTY) last released its quarterly earnings results on Monday, October 27th. The company reported $1.18 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.04. The business had revenue of $698.95 million for the quarter, compared to analysts’ expectations of $699.75 million. Revvity had a net margin of 8.44% and a return on equity of 7.52%. The firm’s revenue for the quarter was up 2.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.28 earnings per share. Revvity has set its FY 2025 guidance at 4.900-5.000 EPS.

Hedge Funds Weigh In On Revvity

Large investors have recently made changes to their positions in the stock. Apollon Wealth Management LLC bought a new stake in shares of Revvity during the 1st quarter valued at $213,000. Wealthfront Advisers LLC lifted its stake in Revvity by 8.9% in the 1st quarter. Wealthfront Advisers LLC now owns 8,988 shares of the company’s stock worth $951,000 after purchasing an additional 731 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in Revvity by 2.8% in the 1st quarter. Victory Capital Management Inc. now owns 72,225 shares of the company’s stock valued at $7,641,000 after purchasing an additional 1,975 shares during the period. Allianz Asset Management GmbH boosted its holdings in Revvity by 13.5% in the 1st quarter. Allianz Asset Management GmbH now owns 136,911 shares of the company’s stock valued at $14,485,000 after purchasing an additional 16,265 shares during the period. Finally, Choreo LLC grew its position in shares of Revvity by 9.9% during the 1st quarter. Choreo LLC now owns 3,829 shares of the company’s stock valued at $405,000 after purchasing an additional 346 shares in the last quarter. 86.65% of the stock is owned by institutional investors.

Revvity announced that its Board of Directors has initiated a share buyback program on Monday, October 27th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 8.7% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its stock is undervalued.

Revvity Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 6th. Investors of record on Friday, January 16th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Friday, January 16th. Revvity’s payout ratio is currently 14.07%.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.